CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vividion Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vividion Therapeutics Inc
5820 Nancy Ridge Dr
Phone: (858) 345-4690p:858 345-4690 SAN DIEGO, CA  92121  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 8/5/2021.
This is a Subsidiary, click here for the Parent Company
Business Summary
Vividion Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in utilizing discovery technologies to unlock traditionally undruggable targets with precision therapeutics for cancers and immune disorders. The Company’s chemoproteomic platform technology addresses the conventional screening techniques and allows to discover previously unknown, or cryptic, functional pockets on the surface of proteins and identify small molecules that selectively bind to those targets. The Company is advancing a diversified pipeline of small molecule therapeutics targeting disease-causing proteins in oncology and immunology with its lead programs targeting two transcription factors, NRF2 and STAT3, and a DNA damage response protein, WRN. NRF2 is a transcription factor that induces a gene transcription program that renders cells resistant to oxidative and other forms of stress. STAT3 is developing orally bioavailable inhibitors for inflammatory diseases and cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202112/31/2020YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer AleksandraRizo
Chief Financial Officer PattyAllen
Senior Vice President - Head of Operations and Alliances JeanBemis
Senior Vice President - Head of Biology ToddKinsella 1/1/2022 1/1/2017
Senior Director of Human Resources AlexisMcwilliams 1/1/2017 1/1/2017

General Information
Number of Employees: 108 (As of 3/31/2021)
Outstanding Shares: 237,759,129 (As of 3/31/2021)
Federal Tax Id: 464373293
Fax Number: (302) 636-5454
Email Address: information@vividion.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 4, 2024